Dendreon tripling workforce ahead of expected vax launch

Over the years Seattle-based Dendreon made a global name for itself as it developed one of the world's first therapeutic vaccines. It's also advanced the careers of scores of biotech executives who have gone on to a wide variety of other drug developers.

"Anybody who can sustain through what Dendreon has sustained--it's a good sign of who they are," Martin Simonetti, the former chief financial officer at Dendreon and now CEO of Seattle-based VLST, tells Xconomy's Luke Timmerman. "You really had a lot of entrepreneurial risk-takers there. There were a lot of good people that made good things happen."

Timmerman carefully tracked down the whereabouts of a long lineup of Dendreon alumni. And Dendreon is promising to help jazz the Seattle biotech scene with plenty of new development veterans. The company tells Xconomy that its workforce, 200 a year ago, is growing to 600 this year as it prepares for a highly-anticipated regulatory decision on Provenge.

- check out the Xconomy story to see where Dendreon veterans have landed

Suggested Articles

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.